SPC 5001

Drug Profile

SPC 5001

Alternative Names: SPC-5001

Latest Information Update: 21 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Antisense RNA inhibitors; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 04 May 2011 Phase-I clinical trials in familial Hypercholesterolaemia in the Netherlands (SC)
  • 04 May 2011 Phase-I clinical trials in Hypercholesterolaemia (in volunteers) in the Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top